Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 258 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTOS/pioglitazone Clear all
Completed No phase listed Observational

Pioglitazone and Quetiapine XR Pharmacogenetic Study

NCT01342380
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 17, 2026, 6:37 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

NCT00722917
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
TAK-379, Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Artesia, California • Norwalk, California • Santa Ana, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Early Phase 1 Interventional Results available

Pioglitazone for Idiopathic Gastroparesis

NCT04300127
View directory record Official record
Conditions
Gastroparesis
Interventions
Pioglitazone 30 mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

NCT01082120
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

NCT01280695
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
14
States / cities
Goodyear, Arizona • Chula Vista, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 4 Interventional Results available

Pioglitazone in Patients With Mood Disorders

NCT01559857
View directory record Official record
Conditions
Major Depressive Disorder, Insulin Resistance
Interventions
Pioglitazone, Sugar Pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 4 Interventional Results available

Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

NCT01002547
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
pioglitazone-placebo, pioglitazone, Vitamin E, Vitamin E-placebo
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease

NCT00322868
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
pioglitazone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 17, 2026, 6:37 AM EDT
Terminated Phase 3 Interventional Results available

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

NCT02284906
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Phoenix, Arizona • Sun City, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 2 Interventional

A Study of Aleglitazar in Patients With Type 2 Diabetes

NCT00388518
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Actos, Placebo, aleglitazar
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Phoenix, Arizona • Beverly Hills, California • Palm Springs, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 17, 2026, 6:37 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pioglitazone to Treat Opioid Withdrawal Symptoms

NCT01517165
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 1 Interventional

Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus

NCT00545857
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
pioglitazone, Placebo control
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Not applicable Interventional Results available

Effect of Thiazolidinediones on Human Bone

NCT00927355
View directory record Official record
Conditions
Osteoblast, Adipocytes, Bone Density, Osteocalcin, Adiponectin, Mesenchymal Stem Cells
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

NCT00762736
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone and azilsartan, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
64
States / cities
Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 17, 2026, 6:37 AM EDT
Terminated Phase 3 Interventional

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

NCT00226330
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
110
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 2 Interventional

Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage

NCT00827892
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Pioglitazone, Placebo Control
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude

NCT06164665
View directory record Official record
Conditions
High Altitude
Interventions
Pioglitazone 15mg, Placebo
Drug · Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 39 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 4 Interventional

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

NCT00926614
View directory record Official record
Conditions
Hepatitis c
Interventions
pioglitazone (Actos), atorvastatin (Lipitor)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

NCT01174056
View directory record Official record
Conditions
Lung Inflammation
Interventions
Zileuton, Pioglitazone placebo, Zileuton placebo, Pioglitazone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 2 Interventional

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

NCT00013598
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 6:37 AM EDT
Terminated Phase 2 Interventional Results available

Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer

NCT00923949
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Pioglitazone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 3 Interventional

Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

NCT00237237
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 77 Years
Enrollment
588 participants
Timeline
Started 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PPARγ Agonist Treatment for Cocaine Dependence

NCT02774343
View directory record Official record
Conditions
Cocaine Use Disorder, Alcohol Use Disorder
Interventions
Pioglitazone, Placebo, Therapy, Contingency Management
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 17, 2026, 6:37 AM EDT